Skip to main content

Month: February 2021

Cogent Growth Partners Advises WorkSmart on Acquisition of IT Services Firm RMS Associates

Latest transaction is the fourth deal WorkSmart has closed with Cogent providing M&A advisory servicesATLANTA, Feb. 25, 2021 (GLOBE NEWSWIRE) — Cogent Growth Partners, a buy-side advisor and intermediary for mergers and acquisitions (M&A) in the IT services sector, today announced the successful closing of a fourth acquisition for WorkSmart, the company that simplifies IT for small business. Cogent identified RMS Associates, a Smyrna, Georgia-based managed IT services firm serving the specialized needs of small business, as a potential acquisition candidate for WorkSmart. Cogent then served as the intermediary, assisting both companies in due diligence, deal negotiation and transaction completion. Financial details of the transaction, which was closed January 1, 2021, were not disclosed.“WorkSmart and RMS share a top-down...

Continue reading

Melco Announces Unaudited Fourth Quarter 2020 Earnings

MACAU, Feb. 25, 2021 (GLOBE NEWSWIRE) — Melco Resorts & Entertainment Limited (Nasdaq: MLCO) (“Melco” or the “Company”), a developer, owner, and operator of integrated resort facilities in Asia and Europe, today reported its unaudited financial results for the fourth quarter and full year ended December 31, 2020.Total operating revenues for the fourth quarter of 2020 were US$0.53 billion, representing a decrease of approximately 64% from US$1.45 billion for the comparable period in 2019. The decrease in total operating revenues was primarily attributable to softer performance in all gaming segments and non-gaming operations as a result of the COVID-19 pandemic, which resulted in a significant decline in inbound tourism throughout 2020 which continued through the fourth quarter.Operating loss for the fourth quarter of 2020 was...

Continue reading

Early Warning Report Moneta Porcupine Mines Inc.

TORONTO, Feb. 25, 2021 (GLOBE NEWSWIRE) — In accordance with regulatory requirements, Dundee Corporation (TSX: DC.A) (“Dundee”) announces that following closing of the transactions described in the news release issued by Moneta Porcupine Mines Inc. (the “Issuer”) dated February 24, 2021 (the “Transactions”), Dundee’s position in the Issuer has been diluted.Dundee and its affiliates own or control 40,081,000 common shares and warrants exercisable for the purchase of 2,148,975 common shares of the Issuer. Immediately prior to the Transactions, Dundee and its affiliates owned or controlled 10.15% of the Issuer on an undiluted basis and 10.63% on a partially diluted basis. Following the Transactions, Dundee owns 7.24% of the Issuer on an undiluted basis and 7.60% on a partially diluted basis.Dundee’s ownership or control of securities...

Continue reading

10x Genomics to Present at the 41st Annual Cowen Health Care Conference

PLEASANTON, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) — 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming 41st Annual Cowen Health Care Conference.10x Genomics’ management is scheduled to present on Wednesday, March 3 at 2 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: https://investors.10xgenomics.com/.About 10x Genomics10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company’s integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers...

Continue reading

Berkeley Lights to Participate in the Cowen 41st Annual Healthcare Conference

EMERYVILLE, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) — Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, today announced the company will be participating in the upcoming Cowen 41st Annual Healthcare Conference.Berkeley Lights’ management is scheduled to participate in a fireside chat on Thursday, March 4 at 11:10 a.m. Pacific Time / 2:10 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.berkeleylights.com.About Berkeley LightsBerkeley Lights is a leading Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional and genotypic...

Continue reading

Albireo Reports Q4 and Year-End 2020 Financial Results and Business Update

– NDA and MAA for odevixibat accepted, on track for anticipated H2 21 launch –– Announces odevixibat co-promotion agreement with Travere, a leading rare disease company –– ASSERT global pivotal Phase 3 trial in Alagille syndrome initiated and enrolling –– BOLD global pivotal Phase 3 study in biliary atresia initiated and enrolling –– Pipeline expansion with two new lead compounds in adult cholestatic and viral liver diseases –– Company to host a conference call and webcast today at 10:00 a.m. ET –BOSTON, Feb. 25, 2021 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare pediatric liver disease company developing novel bile acid modulators, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2020.“2020 was a tremendous year as we delivered...

Continue reading

Pacira BioSciences Reports Full-Year and Fourth Quarter 2020 Financial Results

— Reports record full-year 2020 revenue of $429.6 million  —— Anesthesia-driven regional approaches expanding and driving strong EXPAREL growth —— Conference call today at 8:30 a.m. ET —PARSIPPANY, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the fourth quarter and full-year of 2020.“Our nation’s opioid crisis has escalated under the shadow of the COVID-19 pandemic, as isolation and lack of access to healthcare has exacerbated mental health challenges, particularly addiction. I am delighted to report that EXPAREL-based protocols are expanding opioid-sparing pain management for a variety of procedures where historically poor postsurgical pain management fueled...

Continue reading

MannKind Corporation Reports 2020 Fourth Quarter and Full Year Financial Results

Conference Call to Begin Today at 9:00 AM ET4Q 2020 Afrezza Net Revenue of $10.1 million; +30% vs. 4Q 2019     • Sequential Quarter Growth +38% vs. 3Q 20202020 Total Revenues of $65.1 million     • 2020 Afrezza Net Revenue of $32.3 million; +28% vs. 2019     • 2020 Afrezza Gross Profit $17.2 million; 53% Gross Margin$67.2 million of Cash, Cash Equivalents and Restricted Cash at December 31, 2020Acquired QrumPharma Inc. for $12.8 million in cash and stockEntered into an agreement to co-promote Thyquidity beginning 1Q 2021WESTLAKE VILLAGE, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) — MannKind Corporation (NASDAQ:MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2020.“Our fourth quarter produced exceptional results, with $10.1 million in Afrezza net revenue and positive clinical data for Tyvaso...

Continue reading

Oncocyte Closes Second Investment In Razor Genomics to Complete Acquisition

IRVINE, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) — Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, has closed its previously announced second investment in Razor Genomics (“Razor”), and now owns all of Razor’s outstanding shares. In September 2019 Oncocyte acquired the rights to develop and market Razor’s treatment stratification test, now known as DetermaRx™, Oncocyte’s lead diagnostic test, through certain agreements entered into with Razor. At that time, Oncocyte was granted an option to purchase the outstanding shares of Razor common stock, which Oncocyte agreed to exercise upon the achievement of certain milestones by Razor.On January 29, 2021, Razor informed Oncocyte that those milestones had...

Continue reading

AgroFresh Solutions Announces Fourth Quarter and Full Year 2020 Earnings Release Date

PHILADELPHIA, Feb. 25, 2021 (GLOBE NEWSWIRE) — AgroFresh Solutions, Inc. (Nasdaq: AGFS), a global leader in produce freshness solutions, today announced that it will release fourth quarter and full year 2020 results after the market closes on Wednesday, March 10, 2021, followed by a conference call at 4:30 p.m. ET to discuss the results.Conference CallThe Company will host a conference call and webcast on Wednesday, March 10, 2021, at 4:30 p.m. ET where members of the executive management team will discuss fourth quarter and full year 2020 results with additional comments and details. The conference call and supplemental earnings presentation will be available live over the internet through the “Events & Presentations” page of the Investor Relations section of the Company’s website at www.agrofresh.com. To participate...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.